Abstract:The expanding gene‐editing toolbox has driven a biomedical revolution. These molecular tools tremendously contribute to the progression of fundamental research, such as epigenetics, drug development, disease modeling, and disease diagnosis. Furthermore, therapeutic gene editing offers a profound opportunity to improve the current treatment of human diseases. The expanding genome editing toolbox has revolutionized life science research ranging from the bench to the bedside. These "molecular scissors" have offered us unprecedented abilities to manipulate nucleic acid sequences precisely in living cells from diverse species. Continued advances in genome editing exponentially broaden our knowledge of human genetics, epigenetics, molecular biology, and pathology. Currently, gene editing‐mediated therapies have led to impressive responses in patients with hematological diseases, including sickle cell disease and thalassemia. With the discovery of more efficient, precise and sophisticated gene‐editing tools, more therapeutic gene‐editing approaches will enter the clinic to treat various diseases, such as acquired immunodeficiency sydrome (AIDS), hematologic malignancies, and even severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. These initial successes have spurred the further innovation and development of gene‐editing technology. In this review, we will introduce the architecture and mechanism of the current gene‐editing tools, including clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR‐associated nuclease‐based tools and other protein‐based DNA targeting systems, and we summarize the meaningful applications of diverse technologies in preclinical studies, focusing on the establishment of disease models and diagnostic techniques. Finally, we provide a comprehensive overview of clinical information using gene‐editing therapeutics for treating various human diseases and emphasize the opportunities and challenges.

Editorial: Genome Editing Goes Beyond CRISPR with the Emergence of 'Bridge' RNA Editing

SgRNA Engineering for Improved Genome Editing and Expanded Functional Assays.

Programmable RNA base editing via targeted modifications

Prime editing for precise and highly versatile genome manipulation

CRISPR technologies for genome, epigenome and transcriptome editing

Base editing: precision chemistry on the genome and transcriptome of living cells

To Cut or Not to Cut: Next-generation Genome Editors for Precision Genome Engineering

Gene and RNA Editing: Methods, Enabling Technologies, Applications, and Future Directions

Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors

Next-generation CRISPR technology for genome, epigenome and mitochondrial editing

Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing

Advancing CRISPR base editing technology through innovative strategies and ideas

Rapidly evolving genome and epigenome editing technologies

Current status of genome editing technologies: special issue of BMB Reports in 2024

Oligonucleotide-directed gene-editing technology: mechanisms and future prospects

Programmable RNA-guided enzymes for next-generation genome editing

DNA base editing in nuclear and organellar genomes

Current landscape of gene‐editing technology in biomedicine: Applications, advantages, challenges, and perspectives

CRISPR-Cas13: Pioneering RNA Editing for Nucleic Acid Therapeutics

CRISPR-Cas guides the future of genetic engineering

CRISPR-Cas9 DNA Base-Editing and Prime-Editing